Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/25/2005US6958343 Treating psoriasis, a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or COPD.
10/25/2005US6958339 Pyrazole derivative
10/25/2005US6958338 E.g., 5-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-indole; partial agonists or antagonist at the dopamine D4 receptors; psychoses, schizophrenia, cognition activators; attention deficit disorder; dyskinesia; side effects reduction
10/25/2005US6958336 Anticancer agents; immunosuppressants; antiallergens; antiinflammatory agents
10/25/2005US6958335 Use of imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-y l) pyrimidin-2-ylamino)phenyl)-benzamide or a pharmaceutically acceptable salt
10/25/2005US6958332 Treating an interleukin-12 overproduction-related disorder; treating rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
10/25/2005US6958330 useful as synthetic intermediates in the preparation of inhibitors of beta-amyloid peptide release described in U.S. patent application Ser. No. 08/996,422; 5-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one for example
10/25/2005US6958329 1-[3-Methyl-1-(5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]-azepin-7-ylcarbamoyl)-butyl]-cyclohexanecarboxylic acid amide; inhibit processing of amyloid precursor protein (production of A beta -peptide); neurological disorders related to beta -amyloid production: Alzheimer's disease, Down's Syndrome
10/25/2005US6958327 18 Norsteroids as selectively active estrogens
10/25/2005US6958326 Estrogen complexes; stabilization
10/25/2005US6958325 Biodegradabel polysaccharide derivative for use in human therapeutic and diagnostics
10/25/2005US6958324 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
10/25/2005US6958320 Sel-12 related methods
10/25/2005US6958319 Stability and longer shelf life; bortezomib N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
10/25/2005US6958241 Liposomes with outer surfaces having an affinity moiety that binds to a biological therapy target surface, and a hydrophilic polymer coating reversibly conjugated to said moiety; e.g. polymyxin B conjugate liposome for septic shock
10/25/2005US6958238 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof
10/25/2005US6958233 Generating S-adenosyl-L-methionine; obtain yeast, incubate in nutrient broth, lyse, filter, elute and recover s-adenosyl-l-methionine
10/25/2005US6958220 Inhibitors of proteasomal activity for stimulating hair growth
10/25/2005US6958218 Detecting modulators of brain membrane protein; obtain membrane protein, incubate with ligand and labeled compound, measure level of binding
10/25/2005US6958161 Stable, in release profile after storage of a preparation
10/25/2005US6958160 liposomes include diacylglycerol-PEG compounds; melting point below about 40 degrees C, and acyl chains greater than or equal to 14 carbons in length; use in drug delivery, diagnostics, cosmetics, cosmeceuticals and nutraceuticals
10/25/2005US6958159 Pharmaceutical gel composition
10/25/2005US6958156 Bioavailability, solubility; dietetic adjuvant, foods, cosmetics
10/25/2005US6958153 topical formulation of azithromycin / clarithromycin macrocyclic lactone antibiotic or Tacrolimus/ Sirolimus immunosuppressive macrolide and permeation modulator; minimizes systemic exposure treating at site reduced side effects; scalp conditions
10/25/2005US6958145 Synthesis of cyclic compounds
10/25/2005US6958143 Aftersmoking; converting nicotine to cotinine; discharing in urine
10/25/2005US6958142 Nasal spray formulation and method
10/25/2005CA2440764C Combination of brimonidine and timolol for topical ophthalmic use
10/25/2005CA2429724C Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
10/25/2005CA2359708C Ketolide antibiotics
10/25/2005CA2332461C New benzenesulfonamide derivatives, their method of preparation and the pharmaceutical compositions containing them
10/25/2005CA2331053C Compositions and methods for treating conditions responsive to estrogen
10/25/2005CA2331009C Compositions and methods of treatment for conditions responsive to testosterone elevation
10/25/2005CA2329172C Storage stable extended release oral dosage composition comprising desloratadine and pseudoephedrine
10/25/2005CA2304974C 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
10/25/2005CA2304657C Treatment of conduct disorder
10/25/2005CA2298238C Controlled release by extrusion of solid amorphous dispersions of drugs
10/25/2005CA2284879C Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
10/25/2005CA2266468C Preparation of 1-butyl-4-piperidinylmethylamine
10/25/2005CA2261725C Piperidine and piperazine derivatives and their use as muscarinic antagonists
10/25/2005CA2251232C Method for gene transfer to the central nervous system
10/25/2005CA2227887C Pharmaceutical compositions of conjugated estrogens and methods for their use
10/25/2005CA2197865C Oestradiol-containing transdermal therapeutic system comprising hydrophylic additives
10/25/2005CA2147056C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
10/25/2005CA2144441C Dexpanthenol-containing plaster for the transdermal application of steroid hormones
10/25/2005CA2120782C Thioxanthenone antitumor agents
10/25/2005CA2110454C 1,5,7-trisubstituted indoline compounds for the treatment of dysuria
10/25/2005CA2084301C Heparin derivatives and process for the preparation thereof
10/23/2005CA2504796A1 Polymorphs of pantoprazole sodium salt and process for the preparation thereof
10/21/2005CA2504582A1 Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer
10/21/2005CA2504401A1 Drug delivery systems for the prevention of neointimal hyperlasia
10/20/2005WO2005098444A2 Monocarboxylate transporters expressed in cancer cells
10/20/2005WO2005098027A1 Combination therapies with epothilones and carboplatin
10/20/2005WO2005097995A1 CANCER THERAPY VIA THE INHIBITION OF Skp-2 EXPRESSION
10/20/2005WO2005097993A2 Immunostimulatory viral rna oligonucleotides
10/20/2005WO2005097869A1 Polymers comprising ion channel modulating compounds and uses thereof
10/20/2005WO2005097833A1 Functionalized organic oligomers using homogeneous modification method for molecular binding
10/20/2005WO2005097816A1 Avermectin and avermectin monosaccharide substituted in the 4”- and 4’- position respectively
10/20/2005WO2005097814A2 Composition and method for inhibiting platelet aggregation
10/20/2005WO2005097813A1 Demethyl-cantharidin platinum complex isomers and their use
10/20/2005WO2005097804A1 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
10/20/2005WO2005097803A1 Novel water-soluble prodrug
10/20/2005WO2005097801A1 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
10/20/2005WO2005097800A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
10/20/2005WO2005097799A1 Pyrazolo`4,3-d! pyrimidines
10/20/2005WO2005097796A2 Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
10/20/2005WO2005097795A1 Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
10/20/2005WO2005097793A1 An improved process for the preparation of n-([1,2,4]triazolopyrimidin-2-yl)aryl sulfonamides
10/20/2005WO2005097792A1 Device and method for pneumatic valve control
10/20/2005WO2005097791A1 Inhibitors of iap
10/20/2005WO2005097790A1 Hetaryloxy-substituted phenylamino pyrimidines as rho kinase inhibitors
10/20/2005WO2005097789A1 Novel crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
10/20/2005WO2005097788A2 Sulfonamides and uses thereof
10/20/2005WO2005097787A2 Novel benzothiazoles and the use thereof as medicaments
10/20/2005WO2005097786A1 Oxadiazolone derivatives as ppar delta agonists
10/20/2005WO2005097785A1 Novel diazine derivatives, their manufacture and use as pharmaceutical agents
10/20/2005WO2005097782A1 Piperidine derivative
10/20/2005WO2005097781A1 Quinines-4-substituted derivatives, method and intermediates for the preparation thereof and pharmaceutical compositions containing said derivatives
10/20/2005WO2005097779A1 Diarylamine derivatives as calcium channel blockers
10/20/2005WO2005097777A1 New process for the preparation of diazine derivatives
10/20/2005WO2005097775A1 Piperidine derivates for the treatment of chemokines mediared disease
10/20/2005WO2005097774A1 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
10/20/2005WO2005097772A1 Chromone complexes
10/20/2005WO2005097770A1 Novel hydroxamates as therapeutic agents
10/20/2005WO2005097768A2 Novel gamma secretase inhibitors
10/20/2005WO2005097766A1 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
10/20/2005WO2005097764A1 Thiazole derivative
10/20/2005WO2005097763A2 1,3,4-oxadiazol-2-ones as ppar delta
10/20/2005WO2005097762A2 1,3,4-oxadiazol-2-ones as ppar delta modulators
10/20/2005WO2005097760A1 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
10/20/2005WO2005097758A1 Certain triazole-based compounds, compositions, and uses thereof
10/20/2005WO2005097757A2 Nucleoside derivatives and therapeutic use thereof
10/20/2005WO2005097751A2 Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
10/20/2005WO2005097750A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005WO2005097747A1 Histone deacetylase inhibitor prodrugs
10/20/2005WO2005097744A1 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms)
10/20/2005WO2005097738A1 Novel sulfonamide derivative
10/20/2005WO2005097730A2 Method of exchanging anions of tetraalkylammonium salts
10/20/2005WO2005097729A2 Method for the synthesis of quaternary ammonium compounds and compositions thereof
1 ... 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 ... 7860